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Background: The investigation of treatmentmechanisms in randomized controlled trials has considerable clinical
and theoretical relevance. Despite the empirical support for the effect of mindfulness-based cognitive therapy
(MBCT) in the treatment of recurrent major depressive disorder (MDD), the speciﬁc mechanisms by which
MBCT leads to therapeutic change remain unclear.
Objective: Bymeans of a systematic reviewwe evaluate how the ﬁeld is progressing in its empirical investigation
of mechanisms of change in MBCT for recurrent MDD.
Method: To identify relevant studies, a systematic searchwas conducted. Studieswere coded and ranked for quality.
Results: The search produced 476 articles, ofwhich 23were included. In linewith the theoretical premise, 12 studies
found that alterations in mindfulness, rumination, worry, compassion, or meta-awareness were associated with,
predicted or mediated MBCT's effect on treatment outcome. In addition, preliminary studies indicated that alter-
ations in attention,memory speciﬁcity, self-discrepancy, emotional reactivity andmomentary positive and negative
affect might play a role in howMBCT exerts its clinical effects.
Conclusion: The results suggest that MBCT could work through some of the MBCT model's theoretically predicted
mechanisms. However, there is a need for more rigorous designs that can assess greater levels of causal speciﬁcity.© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
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culminated in recognition of several treatments that have strong evi-
dence in their behalf. Despite this progress, research advances are sorely
needed in studying the mediators and mechanisms of therapeutic
change. It is remarkable that after decades of psychotherapy research,
we can not provide an evidence-based explanation for howorwhy even
our most well studied interventions produce change’ (Kazdin, 2007,
p. 23)
1. Introduction
Mindfulness-based cognitive therapy (MBCT) is an evidence-based
psychotherapeutic intervention that integrates selected elements of
cognitive behavioral therapy for depressionwith the clinical application
of mindfulness meditation (Segal, Williams, & Teasdale, 2013). MBCT is
currently recommended in several national clinical guidelines as a pro-
phylactic treatment for recurrent major depressive disorder (e.g.
National Institute for Clinical Excellence, 2009), and is considered a
cost-effective intervention. MBCT takes the form of 8 weekly group ses-
sions, an all-day silent retreat, and individual daily homework in
between sessions. Since the ﬁrst edition of the MBCT manual was pub-
lished in 2002, there has been a mounting interest in MBCT and its clin-
ical potential in the prophylactic treatment of depressive disorders
(Williams & Kuyken, 2012).
Major depressive disorder (MDD) is one of the most prevalent and
debilitating affective disorders. MDD severely affects psychological, so-
cial and biological functioning, and it is associated with a high degree
of subjective distress. The lifetime prevalence rate of MDD is estimated
around 16% (Kessler et al., 2009), and according to theWorld HealthOr-
ganization MDD is currently the leading cause of disability worldwide
(World Health Organization, 2012). Much of the burden of MDD is a
consequence of MDD often taking a recurrent course. After one episode
of MDD recurrence risk is about 50%, yet the risk of recurrence increases
with every episode, and after 3 episodes the risk of recurrencemay be as
high as 90% (Kessing et al., 2004). Thus, optimizing treatments for recur-
rent MDD is an important priority within the ﬁeld of mental health.
MBCT is based on amodel of cognitive vulnerability to depressive re-
lapse and recurrence (Segal et al., 2013). The model states that patients
who have experienced several episodes of major depression have a
heightened cognitive vulnerability to depressive relapse and recur-
rence. This heightened cognitive vulnerability is proposed to be aconsequence of increased connectivity between depressed mood and
depressogenic cognition having developed during successive episodes
of major depression (Kuyken, Crane, & Dalgleish, 2012; Segal et al.,
2013). MBCT was developed to target this cognitive vulnerability, and
thereby reduce the likelihood of the conﬁguration of a depressive epi-
sode becoming re-established.
Mindfulness has generally been deﬁned as: ‘the awareness that
emerges through paying attention on purpose, in the present moment, and
non-judgmentally to things as they are’ (Williams, Teasdale, Segal, &
Kabat-Zinn, 2007, p. 47). MBCT offers participants a systematic training
in mindfulness meditation drawing extensively on the mindfulness-
based stress reduction (MBSR) program (Kabat-Zinn, 2013). Through
the practice of mindfulness exercises, such as the body scan, simple
yoga exercises, and prolonged periods of sitting meditation, patients are
taught to become aware of, turn towards and relate non-judgmentally
to the change and ﬂux of thoughts, emotions and bodily sensations, in-
cluding intense bodily sensations and emotional discomfort. In addition,
MBCT contains elements from cognitive behavioral therapy (CBT) such
as psychoeducation about the role of cognition in depression, and exer-
cises to illustrate the interrelatedness of thoughts, emotions, behavior
and physiology in inducing and maintaining depressive symptoms.
The combination of practices to cultivate mindfulness skills and CBT
elements are thought to increasingly enable participants to recognize
the automatic activation of habitual dysfunctional cognitive processes,
e.g. depressogenic rumination, and decenter and disengage from these
dysfunctional processes.
Two recent high-quality meta-analyses have evaluated the effective-
ness of MBCT. Hofmann, Sawyer, Witt, and Oh (2010) investigated the
effect of MBSR andMBCT on symptoms of anxiety and depression across
different clinical groups. In nine studies of MBCT they found a large
pooled within-group effect size (Hedges' g = 0.85) for reduction of de-
pressive symptoms. Piet and Hougaard (2011) conducted a meta-
analysis speciﬁcally aimed to evaluate the effect of MBCT for prevention
of relapse in patients with recurrent MDD in remission. Based on six
large RCTswith a total of 593 participants, they found thatMBCT reduced
the risk of relapse by 34% compared to treatment-as-usual (TAU) or pla-
cebo controls. Furthermore, subgroup analyses revealed a relative risk
reduction of 43% for patients with three or more previous episodes,
while no risk reduction was found for participants with only two epi-
sodes. Finally, results from their meta-analysis indicate that MBCT may
be as effective as prophylactic treatment with maintenance antidepres-
santmedication (m-ADM) for patientswith recurrentMDD in remission.
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sidual depressive symptoms and possibly the risk of relapse for patients
highly vulnerable to dysphoria-induced depressogenic thinking who
have had 2 or less previous episodes of depression, although further re-
search is warranted (Geswind, Peeters, Drukker, Van Os, & Wichers,
2012; Piet & Hougaard, 2011).
Despite an empirically founded theoretical rationale for MBCT and a
rapidly increasing body of controlled clinical trials documenting the
prophylactic efﬁcacy of MBCT, little is known about precisely how and
why MBCT works (Fjorback, Arendt, Ornbøl, Fink, & Walach, 2011;
Piet & Hougaard, 2011). Understanding how and why MBCT can pre-
vent relapse risk is essential for a number of reasons. If we begin to un-
cover and understand the mechanisms by which MBCT can prevent
relapse, we may be able to optimize treatment outcomes, and facilitate
a better selection of patients that will beneﬁt from the treatment
(Holmes, Craske, & Graybiel, 2014; Segal et al., 2013). As research initia-
tives on treatment mechanisms in MBCT have increased exponentially,
there is a need for a review that can identify, synthesize and evaluate
the studies that have investigated possible treatment mechanisms in
MBCT treatment of recurrent MDD. Hence, the aim of this article is to
conduct the ﬁrst systematic review of clinical trials speciﬁcally investi-
gating treatment mechanisms in MBCT treatment of recurrent MDD.
1.1. Theoretical predictions
As background information for the review an overview of the pro-
posed theoretical mechanisms presented in the MBCT manual (Segal
et al., 2013) is ﬁrst warranted. The combination of mindfulness training
and selected elements of CBT is according to the theoretical premise
proposed to:
a) enable participants to increasingly recognize the automatic activa-
tion of habitual dysfunctional cognitive processes, e.g. depressogenic
rumination.
b) decenter and disengage from these dysfunctional processes by
redirecting attention to the unfolding of thoughts, emotions, and
bodily sensations in the present moment.
c) develop a meta-awareness and become able to observe thoughts
and feelings as temporary and automatic events in themind instead
of as facts or true descriptions.
d) relate to the change and ﬂux of thoughts, feelings, and physical sen-
sations with a non-judgmental and compassionate attitude.
Together these abilities are proposed to be mechanisms facilitating a
reduced vulnerability to relapse or recurrence. More speciﬁcally, the in-
crease in meta-awareness and the increased ability to recognize and dis-
engage fromdysfunctional depressogenic cognition, is thought to prevent
the patient from getting caught in a vicious circle of depressogenic think-
ing and mood, that can escalate into a new depressive episode. In addi-
tion, the compassionate attitude inherent in mindfulness meditation is
proposed to be a central ingredient in MBCT having a therapeutic effect
(Kuyken et al., 2010), without which disengaging from and not falling
back into avoidance-driven dysfunctional cognition may be extremely
difﬁcult (Segal et al., 2013).
In addition to the speciﬁc theoreticalmodel behindMBCT, a number of
theoretical models have been developed suggesting trans-diagnostic and
trans-interventional mechanisms across mindfulness-based interven-
tions (MBIs), of which we will provide a short overview. Despite consid-
erable overlap between the various models, it is possible to identify
some general hypothesized mechanisms concerning how MBIs may re-
duce depression risk and build resilience. These include: modiﬁcation of
dysfunctional cognitive biases (e.g. memory, attention and perception);
modiﬁcation of dysfunctional beliefs regarding the self, others and
the world; improved top-down and bottom-up ability to regulate emo-
tions and uncomfortable bodily feeling states; increased interoceptiveexposure and bodily awareness; decreased habitual reactivity and im-
proved self-regulation, increased awareness of positive emotions and
events, and ﬁnally increased awareness of functional and dysfunctional
behavioral patterns (Carmody, 2009; Farb, Anderson, & Segal, 2012;
Garland et al., 2010; Grabovac, Lau, & Willet, 2011; Hölzel, Lazar et al.,
2011; Shapiro, Carlson, Astin, & Freedman, 2006; Vago & Silbersweig,
2012). Biologically, the above proposedmechanisms have been hypothe-
sized to correlate with functional and structural neural plasticity, as well
as epigenetic and monoamine alterations collectively resulting in de-
creased phenotypical vulnerability (e.g., Farb et al., 2012; Hölzel,
Carmody et al., 2011; Vago & Silbersweig, 2012; Young, 2012). However,
common in the theoretical models of trans-diagnostic and trans-
interventionalmechanisms inMBIs is a reliance on amore heterogeneous
evidence-base ranging from cross-sectional to randomized controlled tri-
als with both clinical and non-clinical populations. Thus, we do not know
whether the proposed mechanisms in these models would be generaliz-
able to the prevention of relapse/recurrence risk in recurrent MDD.
1.2. Review aim
Despite the considerable theoretical and empirical support for
MBCT, the speciﬁc mechanisms by which MBCT leads to therapeutic
change remains unclear. Consequently, this systematic review has two
primary aims: i) to investigate the extent to which MBCT can be said
to work in accordance with the MBCT manual's theoretically predicted
mechanisms of change; and ii) to determine the ﬁeld's progress in em-
pirically investigating and understanding the therapeutic mechanisms
of MBCT in the treatment of recurrent MDD, and provide suggestions
for future research.
2. Method
The review was conducted in accordance to the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines
for systematic reviews (Moher, Liberati, Tetzlaff, & Altman, 2009). The
studies were selected based on the following criteria of eligibility:
Eligibility criteria:
Type of studies: Clinical trials on mediation or mechanisms in
MBCT treatment of MDD, reported in English.
Type of participants: Participants aged 18 years or above, diag-
nosed with recurrent MDD according to a formal diagnostic classiﬁ-
cation system.
Type of interventions: MBCT conducted in accordance with the
manual (Segal,Williams & Teasdale 2002; 2013).
2.1. Identiﬁcation of studies
Electronic databases (PubMed, PsycINFO) were searched to locate
studies from the ﬁrst available year to June 2014 using the following
keywords: mindfulness-based cognitive therapy OR MBCT AND
depress*. In addition, reference lists of the identiﬁed articles were
inspected for additional relevant studies. The retrieval process was
checked by two of the authors (AMV and KJP).
2.2. Evaluation of the methodological quality of studies
The quality of studies investigating potential mechanisms can be in-
ﬂuenced by a lack of proper randomization and selection bias. The
methodological quality of study reports was assessed using modiﬁed
Jadad criteria adopted from Coelho, Canter, and Ernst (2007). The
Jadad criteria assess appropriate randomization and description, blind-
ness, and number and reasons for drop-outs (Jadad et al., 1996). As dou-
ble blindness of participants and therapists, as required by the original
Jadad criteria, is not possible, the modiﬁed Jadad score allocates one
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ranging from 0 to 4, with 4 being the highest quality measure available.
2.3. Evaluation of the causal speciﬁcity of studies investigating proposed
mechanisms
The evaluation of the causal speciﬁcity of the employed designs is
based on the framework by Alan Kazdin (2007; 2009; 2011). According
to Kazdin (2007),mechanisms provide explanations of how andwhy an
intervention translates into the events that lead to the outcome. In other
words they are causal links between treatment and outcome (Kazdin,
2009; Kraemer,Wilson, Fairburn, & Agras, 2002). The studies examining
potential mechanisms vary in terms of the speciﬁcity of the articulated
mechanism i.e. their ability to point towards potential mechanisms.
Correlational designs have little predictive ability, and do not enable
causal inferences. Regression analysis enables predictions about poten-
tial mechanisms by determining the statistical relationship between
treatment, suggested mechanism and outcome. Mediational analysis
can determine whether there are important statistical relations be-
tween an intervention, the suggested mechanism and outcome, and
whether the relationship between intervention and outcome becomes
statistically insigniﬁcant when the variance from the mediator variable
is taken out. However, a mediation analysis is not intended to explain
precisely how the change comes about, and neither mediation analysis
nor simpler forms of regression analysis can establish causal speciﬁcity
(Kazdin, 2009). Thus, in the case of relapse prevention measures, it is
important to statistically control for symptom reduction to get an indi-
cation of whether the predictive or mediational effect was primarily a
result of symptom change. Furthermore, including timeline or temporal
precedence measures (i.e. testing whether the hypothesized mediator
changes before the outcome) helps increase the degree of causal speci-
ﬁcity. An optimal measure of temporal precedence includes measuring
symptom change and the mediator variable at several simultaneous
points throughout treatment to access whether the mediator variable
indeed does change before the outcome variable (Kazdin, 2007). Intro-
ducing gradient designs, dismantling designs, experimental manipula-
tions, componential enhancement designs, and individual difference
designs can further increase the degree of mechanism speciﬁcity
(Kazdin, 2011; Kraemer et al., 2002; Kuyken et al., 2010; Murphy,
Cooper, Hollon, & Fairburn, 2009; Piet, Würtzen, & Zachariae, 2012).
The speciﬁc designs of the included studies are described in Table 1,
and evaluated in the Discussion.
3. Results
3.1. Study selection
The study selection process is illustrated in Fig. 1 using the PRISMA
ﬂow diagram (Moher et al., 2009) with reasons for exclusion. The search
produced 476 articles, of which 23 studies fulﬁlled the inclusion criteria
(see Table 1). The main reasons for exclusion were participants not
suffering from recurrentMDD, the intervention not being theMBCT pro-
gram, or the study not investigating potential mechanisms of change.
3.2. Study characteristics
The characteristics of the 23 included studies are summarized in
Table 1. Seventeen out of the 23 studieswere independent trials. Sample
sizes varied from 22 to 255, with a total of 1880 participants.
3.3. Theoretical predicted mediators and potential mechanisms of change
Based on the theoretical premise of the MBCT manual increased
mindfulness skills, meta-awareness and self-compassion and reduced
rumination, worry, and cognitive reactivity have been investigated asmediators and potential mechanisms of MBCT's ability to reduce de-
pressive relapse risk among recurrently depressed individuals.
3.3.1. Mindfulness skills
We identiﬁed eight RCTs and one uncontrolled study that investigat-
ed the role of increased mindfulness skills in the reduction in post-
treatment depressive symptoms or relapse risk. When post-treatment
symptoms of depressionwere used as the outcome variable, it is because
it is generally considered to be a robust marker for relapse risk (Kuyken
et al., 2010; Paykel, 2008). Mindfulness was measured using The Frei-
burg Mindfulness Inventory (FMI) (Walach et al., 2006), the Mindful At-
tention Awareness Scale (MAAS: Brown & Ryan, 2003) or the Kentucky
Inventory of Mindfulness Skills (KIMS: Baer, Smith, & Allen., 2004).
Three out of the nine studies found that increasedmindfulnesswas asso-
ciated with (i.e. correlation analysis) a reduction of post-treatment
symptoms of depression, and one found increased mindfulness to pre-
dict (i.e. regression analysis) relapse risk. Three studies conducted a me-
diation analysis, of which two found that mindfulness skills signiﬁcantly
mediated post-treatment symptoms of depression, yet one study did not
ﬁnd an overall mediational effect of mindfulness except on the ‘accept
without judgement’ submeasure of the KIMS scale.
A dismantling trial enables testing of the effect of a speciﬁc proposed
mechanism of change or active therapeutic ingredient such as mindful-
ness skills.Williams et al. (2014) conducted a large three armdismantling
trial comparing MBCT with both TAU and cognitive psychoeducation
(CPE) as the active control. The CPE group was matched on key non-
speciﬁc and speciﬁc factors, so that the main difference between MBCT
and CPE was a systematic training in mindfulness meditation. Over the
whole group of patients no signiﬁcant advantage of MBCT was found in
comparison to both CPE and TAU, despite a reduction in relapse hazard
of 39%. Thus, omitting mindfulness training did not statistically compro-
mise the treatment effect compared with TAU and CPE in the group as a
whole. However, the authors found that MBCT provided signiﬁcant pro-
tection against relapse for participants with increased vulnerability to de-
pressive recurrence due to a history of childhood trauma compared with
CPE and TAU.
3.3.2. Depressogenic cognition
Seven randomized controlled studies (RCTs), and one pre–post
study with no controls, investigated whether decreased rumination
was associated with, predicted or mediated the therapeutic effect of
MBCT on depressive symptom reduction or relapse risk. Rumination
was measured by the Ruminative Response Scale (RRS: Treynor,
Gonzalez, and Nolen-Hoeksema (2003), the Rumination on Sadness
Scale (RSS: Conway, Csank, Holm, & Blake, 2000) or a laboratory exper-
iment (Van Vugt, Hitchcock, Shahar, & Britton, 2012). Three studies
found that decreased rumination was associated with reduced post-
treatment symptoms of depression and one study found that decreased
rumination signiﬁcantly predicted relapse risk. The prediction was
maintained when controlling for symptom change. In addition, three
studies conducted amediation analysis of which two found amediation
effect. Themediation effect wasmaintainedwhen controlling for symp-
tom change. Two studies did not ﬁnd reduced rumination to be either
associated with or mediating post-treatment symptom reduction or re-
lapse risk.
Two RCTs investigated whether worry mediated depressive symp-
tom reduction. In both cases worry was measured by the Penn State
Worry Questionnaire (PSWQ: Meyer, Miller, Metzger, & Borkovec,
1990). Both trials found that worry signiﬁcantly mediated the effect
on MBCT on post-treatment symptoms of depression (Batink, Peeters,
Geschwind, van Os, & Wichers, 2013; Van Aalderen et al., 2012).
Finally, one RCT found thatMBCT treatmentwas associatedwith de-
creased attempts to suppress negative thoughts (Hepburn et al., 2009),
and it has been hypothesized that decreased thought suppressionmight
be linked to decreased depressogenic cognition. However, the study
was preliminary and it remains to be investigated whether decreased
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cognition and subsequent reduced risk of relapse.
3.3.3. Self-compassion and cognitive reactivity
Cognitive reactivity refers to the ease by which dysphoric mood can
reactivate depressogenic thinking patterns. Kuyken et al. (2010) inves-
tigated the link between MBCT treatment, cognitive reactivity, self-
compassion and relapse risk in a RCT employing mediation analysis.
Cognitive reactivity was operationalized as a change in depressive
thinking during a laboratory mood induction. The measure of self-
compassion was the Self-Compassion Scale (SCS: Neff, 2003). The
MBCT group was tapering out of maintenance antidepressant medica-
tion (m-ADM), while the control group remained on m-ADM. The
study design of comparingMBCTwithm-ADM, which is an active treat-
ment with similar efﬁcacy, enabled testing of effects speciﬁc to MBCT.
MBCT participants had higher cognitive reactivity post-treatment com-
pared to the m-ADM control group, but cognitive reactivity predicted
poorer outcome only for the m-ADM group, and not for the MBCT
group. Furthermore, the authors found a signiﬁcant interaction between
self-compassion and cognitive reactivity, indicating that increased self-
compassion moderated and ‘nulliﬁed’ the relationship between in-
creased cognitive reactivity and relapse risk in the MBCT group. Finally,
increased self-compassion was found to mediate the beneﬁcial effect of
MBCT on post-treatment symptoms of depression.
3.3.4. Meta-awareness and decentering
Meta-awareness, meta-cognitive awareness and decentering are
terms employed interchangeably in the MBCT literature. The terms
refer to the ability to observe thoughts and feelings as temporary and au-
tomatic events in themind, rather than facts or true descriptions of real-
ity (Teasdale et al., 2002). Three RCTs investigated whether increased
decentering or meta-cognition was associated with or predicted symp-
tom improvement or relapse risk following MBCT treatment. Hargus,
Crane, Barnhofer, and Williams (2010) found that in symptomatic pa-
tients MBCT in addition to TAU was associated with increased meta-
awareness of a recent suicidal crisis, which was not the case in the TAU
control group. Meta-awareness of the ‘relapse signature’ was measured
using an adapted version of theMeasure of Awareness and Coping in Au-
tobiographical Memory (MACAM: Moore, Hayhurst, & Teasdale, 1996).
Teasdale et al. (2002) found that increased metacognitive awareness of
negative thoughts and feelings predicted reduced relapse risk in MBCT
plus TAU compared with TAU alone. The ﬁndings remained signiﬁcant
after controlling for symptom change. Meta-cognition was measured
by MACAM. Finally, Bieling et al. (2012) found that signiﬁcant increases
in decentering were associated with MBCT treatment and not with m-
ADM treatment. As in the design by Kuyken et al. (2010), the study de-
sign of comparing MBCT with m-ADM, which is an active treatment
with similar efﬁcacy, enabled testing of effects speciﬁc to MBCT.
Decentering as well as wider experiences and curiosity was measured
by subscales of the Toronto Mindfulness Scale (TMS; Lau et al., 2006),
and The Experiences Questionnaire (EQ: Fresco et al., 2007). Changes
in wider experiences and curiosity predicted lower scores on the Hamil-
ton Rating Scale for Depression at 6-month follow-up, but decentering
did not predict lower depression scores at 6-month follow-up.
3.4. Additional correlational and mediational studies on potential
mechanism of change
3.4.1. Memory speciﬁcity
Overgeneral autobiographical memory (as opposed to speciﬁc) is a
cognitive style associated with major depression and suicidal behavior
(Williams et al., 2000). Furthermore, overgeneral memory and depres-
sive rumination appear to be reciprocally reinforcing (Hargus et al.,
2010; Watkins & Teasdale, 2001). Williams et al. (2000) found that
MBCT treatmentwas associatedwith a decrease in overgeneral autobio-
graphical memory (increased memory speciﬁcity) compared with theTAU control group.Memory speciﬁcitywasmeasuredwith the Autobio-
graphical Memory Test (AMT: Williams & Broadbent, 1986). Hargus
et al. (2010) found thatMBCT in addition to TAUwas associatedwith in-
creased speciﬁcity of relapse signatures, i.e. participants were asked to
describe the symptoms they experienced prior to the most recent
time they felt suicidal or wanted to harm themselves. Relapse signa-
tures were measured by the Relapse Signature of Suicidality Interview
(ReSSI), which was developed speciﬁcally for this study. Both studies
controlled for changes in depressive symptoms. However, the results
are preliminary, and it is unknown whether changes in autobiographi-
cal memory or relapse signature speciﬁcity following MBCT would
play a causal role in reducing relapse risk.
3.4.2. Speciﬁcity of life-goals and goal attainment
Crane, Winder, Hargus, Amarasinghe, and Barnhofer (2012) investi-
gated whether MBCT increased the speciﬁcity of life-goals and per-
ceived likelihood of goal attainment. Lack of goal speciﬁcity has been
identiﬁed as a feature of depression and suicidality, and increasing the
speciﬁcity of life goals may build resilience and reduce risk of relapse
(Crane et al., 2012). Speciﬁcity of life-goals was measured by the Mea-
sure to Elicit Positive Future Goals and Plans (Vincent, Boddana, &
MacLeod, 2004). MBCT participants reported signiﬁcantly more speciﬁc
life-goals post-treatment and evaluated the likelihood of attainment
higher than the waitlist control. Controlling for the impact of changes
in symptoms of depression did not alter the ﬁndings. Nonetheless, it re-
mains to be investigated whether the increases in life goal speciﬁcity
and perceived likelihood of goal attainment are associatedwith a subse-
quent reduction in relapse or recurrence risk. Furthermore, although an
increase in speciﬁcity of life-goals is consistent with a broader increase
in speciﬁcity of self-referent cognition, the way in which MBCT pro-
duces these changes remains unclear.
3.4.3. Self-discrepancy
Crane et al. (2008) explored the effect of MBCT versus TAU on levels
of self-discrepancy in patients in remission from depression with a his-
tory of severe suicidal ideation. Self-discrepancy refers to the perceived
distance between current and idealized self-representations, with high
levels of ideal self-discrepancy being linked to depressed mood. Self-
discrepancy was measured by the Self-Description Questionnaire
(SDQ: Carver, Lawrence, & Scheier, 1999). The study employed a corre-
lational design and found that individuals receiving TAU showed in-
creases in ideal self-discrepancy across the study period, which may
reﬂect increased vulnerability to relapse. The MBCT group showed no
such increase. The ﬁndings were not accounted for by changes in resid-
ual depressive symptoms. However, it is unclear whether the observed
effects of MBCT on self-discrepancy would translate into a reduced risk
of subsequent relapse to depression or whether similar ﬁndings would
be observed in less vulnerable clinical groups of patients with recurrent
MDD.
3.4.4. Attention regulation
MBCT participation may lead to an improved ability to regulate at-
tention and disengage from depressogenic cognition, which may trans-
late into improved treatment outcomes. Van den Hurk et al. (2012)
employed a correlational experimental design and found no changes
in attentional processes (alerting, orienting and executive attention)
or more general attentional functioning in the MBCT group, nor in the
waitlist control group. However, the experimental measure of attention
(Attention Network Test) employed was used to investigate how fast
and how accurately a target stimulus could be detected among alternate
cues and stimuli, and as such may not be the most valid measure of at-
tention regulation associated with training in mindfulness meditation.
Employing a correlational design with a task that is arguably more
representative for attention regulation during mindfulness meditation,
Bostanov, Keune, Kotchoubey, and Hautzinger (2012) explored wheth-
er MBCT was associated with an improved ability to deploy and
Table 1
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Bakker et al. (2014) MBCT vs. waitlist 126 individuals with a
recurrent MDD; residual
depressive symptoms
Positive affect PA (ESM) Gene variation: BDNF,
CHRM2, COMT, DRD2,
DRD4
RCT. Pre–post design.
Correlational analysis
CHRM2 and OPRM1 moderated the positive change in
PA in the MBCT group (boosting effect). Increased
residual depressive symptoms in the control group
were moderated by variation in BDNF and DRD4 genes
(deteriorating effect)
3
Barnhofer et al. (2007) MBCT vs. TAU 22 individuals with a
recurrent MDD; with
history of suicidal
depression
Symptoms of depression (BDI) Left-frontal brain activation
(EEG). Positive and negative
affect (PANAS)
RCT. Pre–post design.
Correlational analysis
The TAU group showed a signiﬁcant deterioration
toward decreased relative left-frontal brain activation
(EEG), while there was no signiﬁcant change in the
MBCT group
3
Batink et al. (2013) MBCT vs. TAU 130 adults with current
residual depressive
symptoms (N1 PE)
Symptoms of depression (HDRS) Mindfulness (KIMS); worry
(PSWQ); rumination (RSS);
momentary positive and
negative affect (ESM)
RCT. Pre–post design.
Mediation analysis
Momentary positive and negative affect (MPNA),
mindfulness skills and worry mediated the efﬁcacy of
MBCT. MPNA also mediated the effect of worry on
depressive symptoms. Subgroup mediation: ≤2
episodes of MDD: cognitive and affective processes
mediated the effect of MBCT; ≥3 episodes of MDD,
affective processes mediated for the effect of MBCT
3
Bieling et al. (2012) MBCT vs. M-ADM 85 individuals with a
recurrent MDD in
remission (treated
with ADM during the
acute phase)
Symptoms of depression
(HDRS) with 6-month
follow-up
Decentering, curiosity and
wider experiences (EQ, TMS)
RCT. Pre-ADM treatment,
pre-MBCT treatment
and post-MBCT treatment
with 6 month follow-up.
Correlation and
regression analysis
Post intervention, MBCT showed signiﬁcant increases in
wider experiences and decentering, whereas m-ADM
patients did not. Curiosity and wider experiences, but
not rumination and decentering, predicted depressive
symptoms at follow-up. Rumination did not
demonstrate MBCT speciﬁc changes
3
Bostanov et al. (2012) MBCT vs. waitlist 91 individuals with a
recurrent MDD in remission
Late CNV (LCNV) response Attention regulation
(LCNV response)
RCT. Pre–post design.
Correlation analysis
The late contingent negative variation (CNV), an
event-related brain potential (ERP) was increased only
after MBCT (mindfulness breathing task with auditory
stimulus and mood induction)
3
Britton et al. (2012) MBCT vs. waitlist 52 individuals with a
recurrent MDD in partial
remission (N3 PE)
Symptoms of depression (HDRS) Anxiety (STAI), measured
during and after Trier Social
Stress Test (TSST)
RCT. Pre–post design.
Mediation analysis
Improvements in anxiety regulation partially mediated
the effects of MBCT on depressive symptoms
3
Crane et al. (2008) MBCT vs. waitlist 68 individuals with a
recurrent MDD. In remission.
With a history of suicidal
ideation
Symptoms of depression (BDI-II) Ideal and ought
self-discrepancy (SDQ)
RCT. Pre–post design.
Correlation design
MBCT reduced residual depressive symptoms. The
MBCT group reported signiﬁcantly lower levels of
discrepancy from their ideal self post-treatment than
the waitlist control
3
Crane et al. (2012) MBCT vs. waitlist 27 recurrently individuals
with a recurrent MDD with
or without a currently
symptomatic episode.
With a history of suicidal
ideation
Symptoms of depression (BDI-II) Memory speciﬁcity (AMT);
life-goal speciﬁcity (MEPFG)
RCT. Pre–post design.
Mediation analysis
Depressive symptoms mediated the effect of
intervention on perceived likelihood of goal
attainment. Increases in goal speciﬁcity were
associated with parallel increases in autobiographical
memory speciﬁcity. Increases in goal likelihood were
associated with reductions in depressed mood
4
De Raedt et al. (2012) MBCT vs.
non-intervention.
45 participants individuals
with a recurrent MDD
Symptoms of depression
(BDI-II; MINI; HDRS)
Attention (NAP);
mindfulness (MAAS)
Non-randomized,
controlled. Pre–post
design. Correlation
analysis
After MBCT, participants showed a reduced facilitation
of attention for negative information and a reduced
inhibition of attention for positive information. The
control group showed no change in affective
information facilitation
0
Geswind et al. (2012) MBCT vs. waitlist 130 individuals with a
recurrent MDD with
current residual
depressive symptoms
Symptoms of depression (HDRS) Pleasantness of daily life
activities; positive and negative
affect; reward experience; (ESM);
worry (PSWQ); rumination (RSS)
RCT. Pre–post design.
Correlation analysis
Compared to waitlist control, MBCT was associated
with signiﬁcant increases in appraisals of positive
emotion, activity pleasantness, and enhanced ability to
boost momentary positive emotions by engaging in
pleasant activities
3
Hargus et al. (2010) MBCT + (TAU) vs. TAU 27 individuals with a
recurrent MDD (N3 PE).
History of suicidal
ideation or suicidal
behavior
Symptoms of depression (BDI-II)
with 3 month follow-up
Relapse signatures (ReSSI)
coded for: meta-awareness
and memory speciﬁcity
RCT. Pre–post design
with 3 month follow
up. Correlation analysis
Patients randomized to MBCT + TAU displayed
signiﬁcant posttreatment differences in
meta-awareness and speciﬁcity compared with TAU
patients
4
Hepburn et al. (2009). MBCT plus TAU vs. TAU 68 individuals with a
recurrent MDD and a
history of suicidal ideation
Symptoms of depression (BDI-II) Thought Suppression (WBSI) RCT. Pre–post design.
Correlation analysis
Patients randomized to MBCT + TAU did not
display decreased thought suppression, but
reported signiﬁcantly reduced attempts to
suppress
3
Keune et al. (2011) MBCT vs. waitlist 78 individuals with a
recurrent MDD in remission
Symptoms of depression
(BDI-II); trait rumination
Resting-state alpha-asymmetry
(EGG)
RCT. Pre–post design.
Correlation analysis
In comparison with a wait-list control, MBCT reduced
depressive symptoms, trait rumination and increased
3
(continued on next page)
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Table 1 (continued)
Study Intervention Participants Outcome measures Mechanism measures Design and analysis Findings Jadad
(RSQ); trait mindfulness
(FMI)
trait mindfulness. Alpha asymmetry remained
unaffected by training, and changes in rumination and
mindfulness was not correlated with alpha symmetry
Kuyken et al. (2010) MBCT vs. maintenance
antidepressants
(m-ADM)
123 individuals with a
recurrent MDD (N3 PE), in
remission after
treatment with ADM
Symptoms of depression
(HRSD); relapse: (SCID)
at 15 month follow up
Mindfulness (KIMS);
self-compassion (SCS);
cognitive reactivity laboratory
paradigm (Segal, 2006)
RCT. Pre–post and
15 month follow up.
Mediation analysis
Mindfulness and self-compassion mediated the effect
of MBCT on depressive symptoms at 15-month
follow-up. Greater cognitive reactivity predicted
poorer outcome for mADM patients, but not for MBCT
patients
4
Michalak et al. (2008) MBCT (no control group) 24 individuals with a
recurrent MDD in remission
Symptoms of depression
(HRSD; BDI), relapse: SCID
(12 month follow-up)
Mindfulness (MAAS) Not randomized, not
controlled. Pre–post
and 12 month follow up.
Regression analysis
Mindfulness signiﬁcantly increased during MBCT.
Posttreatment levels of mindfulness predicted the risk
of relapse/recurrence to major depressive disorder in
the 12-month follow-up period
0
Michalak, Hölz
& Teismann (2011)
MBCT (no control group) 24 individuals with a
recurrent MDD in remission
Symptoms of depression
(HRSD; BDI), relapse: (SCID)
at 12 month follow-up
Rumination (RRS) Not randomized, not
controlled. Pre–post
and 12 month follow
up. Regression analysis
Rumination signiﬁcantly decreased during MBCT.
Posttreatment levels of rumination predicted the risk
of relapse/recurrence to major depressive disorder in
the 12-month follow-up period
0
Shahar et al. (2010) MBCT vs. waitlist 45 individuals with a
recurrent MDD in partial
remission (N3 PE).
Symptoms of depression
(HRSD; BDI), relapse:
(SCID-I & II) at 15 month
follow-up
Mindfulness (MAAS);
rumination (RRS) modiﬁed
RCT. Pre–post and
15 month follow up.
Mediation analysis
Reductions in brooding (an aspect of rumination) and
increases in mindfulness mediated the effects of the
intervention on depressive symptoms
3
Teasdale et al. (2002) MBCT vs. TAU 87 individuals with a
recurrent MDD in remission
Symptoms of depression
(HRSD; BDI), relapse:
DSM-III-R at bimonthly
assessment over 1 year
Meta-awareness (MACAM)
at 15 weeks post-treatment
RCT. Pre–post design
with 1 year follow
up with bimonthly
assessments.
Regression analysis
Compared with TAU, MBCT reduced relapse risk and
increased metacognitive awareness of negative
thoughts and feelings
3
Van Aalderen
et al. (2012)
MBCT + TAU vs. TAU 205 individuals with a r
ecurrent MDD (N3 PE)
with or without
a current episode
Symptoms of depression and
relapse (HRSD; BDI) at
post-treatment and 3, 6, 9
and 12 months follow-up
Mindfulness (KIMS);
rumination (RSS); quality of Life
(WHOQOL); worry (PSWQ)
RCT. Pre–post design
with 3, 6, 9 and
12 months follow-up.
Mediation analysis
Patients in the MBCT + TAU group reported less
depressive symptoms, worry and rumination and
increased levels of mindfulness skills compared with
patients receiving TAU alone. MBCT resulted in a
comparable reduction of depressive symptoms for
patients with and without a current depressive
episode. Additional analyses suggest that the reduction
of depressive symptoms was mediated by decreased
levels of rumination and worry
3
Van den Hurk
et al. (2012)
MBCT vs. waitlist control 71 individuals with a
recurrent MDD (N3 PE)
Symptoms of depression (HRSD) Attention (ANT); mindfulness
(KIMS); rumination (RSS)
RCT. Pre–post design.
Correlation analysis
In the MBCT group, depressive symptoms and
ruminative thinking decreased and mindfulness skills
increased. No changes in the components of attentional
processes (alerting, orienting and executive attention)
or more general attentional functioning were observed
3
Van Vugt et al. (2012) MBCT vs. waitlist 52 individuals with a
recurrent MDD in partial or
full remission
Symptoms of depression
(BDI), anxiety: STAI-Y1
Rumination: free recall task RCT. Pre–post design.
Correlation analysis
MBCT participants showed a decrease in patterns that
may perpetuate rumination on all three types of recall
dynamics (Pstart, Pstay, and Pstop), compared to
controls
3
Williams et al. (2000) MBCT + TAU vs. TAU 45 individuals with
recurrent MDD in
remission (N2 PE)
Symptoms of depression (HRSD) Memory speciﬁcity (AMT) RCT. Pre–post design.
Correlation analysis
Whereas control patients showed no change in
speciﬁcity of memories recalled in response to cue
words, the MBCT group showed a signiﬁcantly reduced
number of overgeneral autobiographical memories
(increased speciﬁcity)
1
Williams et al. (2014) MBCT + TAU vs
CPE + TAU vs TAU
255 individuals with
recurrent MDD
Relapse: (SCID) at 3, 6,
9, 12 month post-treatment
Mindfulness meditation RCT. Pre–post design
with 1 year follow
up with assessments
every 3 months.
Dismantling design
MBCT showed no signiﬁcant advantage in comparison
to an active control treatment and usual care over the
whole group of patients with recurrent depression.
However, MBCT provided signiﬁcant protection against
relapse for participants with increased vulnerability
due to history of childhood trauma
3
Note: ADM= antidepressant medication; ANT= Attentional Network Test; AMT= Autobiographical Memory Test; BDI = Beck Depression Inventory; BDI-II = Beck Depression Inventory-II; BDNF, brain-derived neurotrophic factor; CHRM2, cho-
linergic receptor muscarinic 2; COMT, catechol-O-methyltransferase; CPE = Cognitive Psycho-Education; DRD2 = Dopamine Receptor D2; DRD4 = dopamine receptor D4; EQ = Experiences Questionnaire; ESM= Experience Sampling Method-
ology; FMI= FreiburgMindfulness Inventory; HDRS=Hamilton Depression Rating Scale; MAAS=Mindful Awareness Attention Scale; m-ADM=maintenance antidepressantmedication;MADRS=Montgomery–Asberg Depression Rating Scale;
MBCT = mindfulness-based cognitive therapy; MDD = major depressive disorder; MINI = Mini International Neuropsychiatric Interview, NAP = Negative Affective Priming Task; PANAS = the Positive And Negative Affect Schedule; TAU =
treatment as usual; KIMS = Kentucky Inventory of Mindfulness Skills; MEPFG = Measure to Elicit Positive Future Goals; PE = Previous Episodes; PSWQ= Penn State Worry Questionnaire; RCT: Randomized Clinical Trial; RSS = Rumination on
Sadness Scale;, RRS = Ruminative Response Scale; ReSSI = Relapse Signature of Suicidality Interview (ReSSI); SCID = Structured Clinical Interview for DSM; SCS = Self-Compassion Scale; SDQ= Self-Description Questionnaire; RSQ-D = Der Re-
sponse Styles Questionnaire-D; STAI-Y = The Spielberger State–Trait Anxiety Inventory form Y; TMS = Toronto Mindfulness Scale; WBSI =White Bear Suppression Inventory (WBSI); WHOQOL = The World Health Organization Quality of Life.
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Fig. 1. Flow of information from identiﬁcation to inclusion of studies.
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breathing task with a mood induction stimuli, and a distracting auditory
stimulus. They found that the late contingent negative variation (CNV)—
an event-related brain potential (ERP)—was increased only after MBCT,
and not in thewaiting list control group. This ﬁndingmay indicate an im-
proved ability to deploy andmaintain attention on a particular focus dur-
ing sad mood. The ﬁnding remained signiﬁcant after controlling for
changes in mood. However, this study is preliminary and it is unclear
whether the attentional effect is of a clinical predictive value.
De Raedt et al. (2012) investigated the effect of MBCT versus no in-
tervention on the facilitation and inhibition of attention for sad and
happy faces in a laboratory experiment with a correlational design
(Negative Affective Priming Task). After MBCT, participants showed
reduced facilitation of attention for negative information and reduced
inhibition of attention for positive information, whereas the no-
intervention control group showed no change in affective information
facilitation. However, due to limitations to the study including a non-
randomized design, evidence of key baseline differences between the
two groups, and ﬁnally a lack of statistical controlling for symptom
change, it is hard to disentangle the ﬁndings from self-selection bias
and group differences.
3.4.5. Affective changes
Positive affect (PA) and daily reward experience may build resil-
ience, and have been associatedwith decreased vulnerability to relapse.
More speciﬁcally, the increased ability to generate PA from pleasant
daily life events has been associated with a three-fold reduction in re-
lapse risk in individuals with recurrent MDD (Geswind et al., 2012).
Geswind et al. (2012) found that MBCT treatment was associated with
reports of increased experience of momentary positive emotions, as
well as greater appreciation of and enhanced responsiveness to pleasant
daily-life activities. Both was measured by the Experience Sampling
Measure (ESM; Csikszentmihalyi & Larson, 1987). The wait-list control
did not report similar increases. The ﬁndings remained signiﬁcant
after controlling for alterations in depressive symptoms, negative emo-
tion, rumination, and worry.Batink et al. (2013) found that changes in momentary positive and
negative affect signiﬁcantly mediated the efﬁcacy of MBCT, as well as
the effect of worry on depressive symptoms, compared with TAU con-
trols. Momentary positive and negative affect was measured by the
ESM. In addition, subgroup analyses revealed that changes in cognitive
processes (i.e. rumination and worry), and to a lesser extent affective
processes (i.e.momentary positive andnegative affect)mediated the ef-
fect of MBCT for patients with a prior history of two or more episodes of
MDD. For patients with three or more previous depressive episodes,
changes in positive and negative affect predominantly mediated the ef-
fect of MBCT on post-treatment symptoms of depression. It remains to
be exploredwhether changes inmomentary positive and negative emo-
tions following MBCT could play a causal role in increasing resilience
and thus reducing risk of relapse.
Emotional reactivity to stress may be amarker of depression vulner-
ability and treatment response (Britton, Shahar, Szepsenwol, & Jacobs,
2012). Britton et al. (2012) investigated whether MBCT treatment
would alter emotional reactivity to stress. Conducting a laboratory ex-
periment, emotional reactivity to stress was assessed with the
Spielberger State-Trait Anxiety Inventory (STAI-Y1: Spielberger,
Gorsuch, Lushene, Vagg, & Jacobs, 1983) before, during, and after the
Trier Social Stress Test (TSST: Kirschbaum, Pirke, & HellHammer,
1993). The MBCT group showed an overall decrease in emotional reac-
tivity, which was not present in the waitlist control group. The de-
creased emotional reactivity to stress in the MBCT group was speciﬁc
to the post-stressor recovery phase. Furthermore, the changes in emo-
tional reactivity partially mediated improvements in symptoms of de-
pression. The study is preliminary with a small sample size, and it
remains to be investigated whether the alteration in emotional reactiv-
ity to stress can predict a reduction in relapse or recurrence risk.
3.5. Neural predictive factors and mechanisms
Neuroimaging research on biomarkers and neural correlates of
MBCT treatment of recurrentMDD is still in its infancy. Our search iden-
tiﬁed only two studies investigating the neural correlates of MBCT
34 A.M. van der Velden et al. / Clinical Psychology Review 37 (2015) 26–39treatment of recurrent MDD. Both measured resting-state prefrontal
[alpha]-asymmetry. Prefrontal asymmetry has been suggested to be a po-
tential neurobiological indicator of affective style and an endophenotype
indicating risk of future episodes of depression (Keune, Bostanov,
Hautzinger, & Kotchoubey, 2011).
Barnhofer et al. (2007) and Keune et al. (2011) investigated the ef-
fect ofMBCT in a remitted recurrently depressed population on prefron-
tal [alpha]-asymmetry with resting electroencephalogram (EEG)
employing correlational designs. Barnhofer et al. (2007) found a signif-
icant deterioration towards decreased relative left-frontal activation in
the TAU control group with no signiﬁcant change in the MBCT group.
Keune et al. (2011) found no difference between the MBCT group and
a waitlist control in a bigger sample, with the whole sample showing
a pattern indicative of stronger relative right anterior cortical activity.
In addition, the observed shift in alpha asymmetry was not strongly as-
sociated with trait rumination or trait mindfulness. Both studies report-
ed having controlled for symptom reduction. However, due to these
contradictory ﬁndings, it is unclear whether MBCT alters alpha asym-
metry more than control treatments. Furthermore, it has been debated
whether prefrontal asymmetry is a valid predictor of affective style,
and a measure of clinical predictive signiﬁcance with regard to relapse
risk (Fjorback et al., 2011).
3.6. Genetic predictive factors and mechanisms
The relevance of investigating the role of genes in psychotherapeutic
treatment of depressive disorders has repeatedly been highlighted in
the literature. Yet, few studies have investigated the relationship be-
tween genes and MBCT treatment of recurrent MDD. Bakker et al.
(2014) investigated the relationship between genes involved in reward
functioning such as genes coding for dopamine and opioid regulation
with changes in positive affect after MBCT treatment. They found that
the muscarinic acetylcholine receptor M2 (CHRM2) and the μ1 opioid
receptor (OPRM1) moderated the positive change in PA in the MBCT
group (boosting effect). The study further found that increased residual
depressive symptoms in the control groupweremoderated by variation
in thebrain-derived neurotrophic factor (BDNF) anddopamine receptor
D4 (DRD4) genes (deteriorating effect). Together the ﬁndings suggest
that the hypothesized mechanism of positive affect may be dependent
on gene variation, and more broadly that gene variation may moderate
the mechanisms by which MBCT works. However, the study examined
only a minor proportion of the human genome, and the majority of
the single nucleotide polymorphisms (SNPs) were either non-coding
or non-functional. Consequently, causal associations between gene var-
iation, positive affect and reduced depressive symptoms remain to be
investigated further in future trials.
3.7. Limitations of the included studies
The reviewed studies have a number of limitations. First, the major-
ity of the examined studies relied mainly on self-report measures of the
mediation or mechanism variables. As participant blinding to the theo-
retically proposed mechanisms in MBCT is not possible, and education
about MBCT's proposed mechanisms is inherent in the MBCT program,
it is not possible to discern to what extent participant perception and
belief in a certainmechanism e.g.mindfulness skills may have impacted
the results. Of the 23 examined studies, seven included more objective
measures such as laboratory experiments and brain imaging, and of
the trials investigating theoretical predicted mechanisms presented in
the MBCT manual only two included more ‘objective’ measures such
as laboratory experiments.
In the measurement of mindfulness, three measures were employed
i.e. The FreiburgMindfulness Inventory (FMI);Mindful AttentionAware-
ness Scale (MAAS) or Kentucky Inventory of Mindfulness Skills (KIMS),
all considered reliable and validated scales. However, the MAAS mea-
sures mindfulness rather narrowly, focusing on mind wandering andnegatively focused items. The acceptance factor has been omitted in
the recent version, and the MAASmay be restricted in its ability to mea-
sure the breath of mindfulness (Bergamo, Tschacher, & Kupper, 2013).
Finally, it is difﬁcult to establish to what extent e.g. increases in
mindfulness and decreases in rumination were a unique result of the
MBCT treatment. In many cases, participants were also on a stable
dose of antidepressant medicine while receiving MBCT, and sometimes
also received treatment as usual, which may include other psychother-
apeutic treatments. Mixed interventions cannot provide a proper indi-
cator of treatment speciﬁc mechanisms, but avoiding such designs
may not be feasible or advisable due to ethical and clinical concerns.
However, in these cases it may be possible to consider sub-group anal-
yses to check for differences among participants who received both
MBCT and ADM, and participants who only received MBCT.
4. Discussion
Despite a rapidly increasing body of controlled clinical trials
documenting MBCT's efﬁcacy, little is known about precisely how and
why MBCT works in the treatment of recurrent MDD. Understanding
how and why MBCT can effectively reduce symptoms of depression
and prevent risk of relapse is essential both for theoretical and clinical
reasons. The importance of examining change mechanisms has been
emphasized throughout the literature (Kazdin, 2011; Murphy et al.,
2009). Research on treatmentmechanisms can inform the scientiﬁc un-
derstanding of the processes leading to therapeutic change, help thera-
pists and treatment developers improve MBCT's outcomes and reﬁne
treatment manuals, and facilitate a better selection of patients who
may beneﬁt from the treatment (Kazdin, 2007; Murphy et al., 2009;
Segal et al., 2013).
The purpose of this article was to assess the ﬁeld's progress in empir-
ically investigating and understanding the mechanisms of change in
MBCT for recurrent MDD, and to investigate the extent to which MBCT
maybeworking in accordancewith theMBCTmanual's theoretically pro-
posed change mechanisms. Towards this aim a systematic literature
search was conducted and 23 studies fulﬁlling the inclusion criteria
were selected for the review process. In line with the theoretical predict-
edmechanisms, twelve studies found that changes in eithermindfulness,
rumination, worry, self-compassion, decentering ormeta-awarenesswas
associated with, predicted or mediated the effect of MBCT on treatment
outcome. In terms of mediation analyses, two out of three studies found
increased mindfulness to mediate treatment outcome. Two out of three
studies found decreased rumination to mediate treatment outcome,
and two out of two studies found decreased worry to mediate treatment
outcome. No studies employed mediation analysis for meta-awareness,
yet one study found increased meta-awareness to predict reduced re-
lapse risk. Finally, one study found increased self-compassion to mediate
reduced relapse risk, and to reduce the predictive relationship between
cognitive reactivity and relapse risk.
Two trials did not ﬁnd evidence for the theoretical predicted vari-
ables of either mindfulness or rumination. It is unclear why the two
studies failed to ﬁnd an effect. The majority of the included trials did
not report on treatment ﬁdelity measures (i.e. therapist competence
and adherence to the MBCT treatment manual), and it is possible that
a lack of adequate treatment ﬁdelity could have led to a type III error
(i.e. the failure to ﬁnd amediation effect due to a lack of treatment ﬁdel-
ity). The inclusion of previous meditation experience in the study by
Van Aalderen et al. (2012) may have contributed to a lack of a differen-
tial effect on themindfulnessmeasure between baseline symptoms and
post-treatment symptoms, and have led to the study not ﬁnding an
overall mediational effect of mindfulness except on the ‘accept without
judgement’ submeasure of the KIMS scale. In the case of rumination,
only 2 out of 3 studies found a signiﬁcant effect. In addition, we are
aware of two previous large trials that examined changes in rumination
without ﬁnding an effect (lack of ﬁndings not published). Hence, con-
sidering the inconsistent results on rumination measures, and the
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the ﬁeld, it may be questionable whether rumination is a key mecha-
nism of change. The study by Kuyken et al. (2010) found that cognitive
reactivity did not decrease in theMBCT group, yet the predictive link be-
tween relapse risk and cognitive reactivity was altered. Likewise, it is
possible that rumination scores do not decrease after MBCT participa-
tion, but that the predictive link between rumination scores and relapse
risk may change, perhaps as a result of reduced identiﬁcation with the
content of negative automatic thoughts. Future studies could beneﬁt
from exploring this possibility further. Furthermore, increased aware-
ness of negative ruminative thoughts may also be a consequence of
MBCT participation. As a result it is possible that rumination does objec-
tively decrease, but that heightened subjective awareness may cause
participants to score relatively higher on rumination self-report ques-
tionnaires. Comparing self-report and laboratory measures of rumina-
tion may be able to address this question in future research.
Eight studies reported preliminaryﬁndings indicating that alterations
in attention regulation ability, memory speciﬁcity, self-discrepancy,
emotional reactivity and momentary positive and negative affect might
play a role in MBCT's effect on treatment outcome. However, it remains
to be explored whether these potential mechanisms can predict de-
creased risk of relapse. In addition, a plausible theoretical account of
why MBCT may cause the respective variables to change needs to be
articulated.
The reviewed studies varied in terms of speciﬁcity in the investiga-
tion of potential mechanisms. Our search identiﬁed 12 correlation anal-
yses, 4 regression analyses, 6 mediation analyses, and 1 trial with a
dismantling design. Two studies employed the recommendations by
Kraemer et al. (2002), ensuring that measurement of the mediator var-
iable temporally preceded measurement of the outcome variable
(Bieling et al., 2012; Kuyken et al., 2010). However, none of the exam-
ined studies includedmeasures of temporal precedence as recommend-
ed by Kazdin (2007; 2009; 2011), where both mediator and symptoms
are measured at several simultaneous points throughout the treatment
period to uncover whether the mediator variable does in fact change
prior to change in the outcome variable. One study employed a disman-
tling design comparing MBCT with an active CPE control group, which
was matched on several non-speciﬁc and speciﬁc factors, with the ex-
ception that theMBCT group included a systematic training in mindful-
ness meditation and associated mindfulness training homework
(Williams et al., 2014). The authors found that MBCT provided signiﬁ-
cant protection against relapse for participants with increased vulnera-
bility due to a history of childhood trauma. However, they did not ﬁnd a
signiﬁcant difference when comparing MBCT to CPE or TAU over the
whole group of patients, despite a reduction in relapse hazard of 39%.
It may be that increased statistical power, adjusted to the expectation
of a small differential effect, would have been required for a signiﬁcant
difference to be detectable between MBCT and control groups such as
TAU or CPE that are likely to produce a signiﬁcant effect in and of them-
selves. The high standards of the TAU control condition in the disman-
tling design by Williams et al. (2014), where many received ADM and
psychoeducation,may have contributed to the lack of signiﬁcant differen-
tial ﬁndings between the less vulnerable groups. A similar design with
CBT have also found that only the more vulnerable populations beneﬁt
more from CBT compared with a psychoeducation active control
(Stangier et al., 2013). It is possible that larger samples based on conser-
vative power estimates may generally be required to ﬁnd signiﬁcant
differences between less vulnerable groups in psychotherapeutic disman-
tling designs. The results of the dismantling trial may also indicate that
other speciﬁc and non-speciﬁc mechanisms e.g. psychoeducation, group
support and expectancy could play a central role in the treatment effect
ofMBCT in less vulnerable populations. Indeed, theﬁnding that the effects
of CPE were intermediate between MBCT and TAU could suggest that
psycho-education and group support provided by bothMBCT and CPE in-
terventions could be mechanisms that explain some of the effects of
MBCT (Williams et al., 2014). Finally, it remains unclear exactly whyMBCT was superior for those with a greater history of childhood trauma,
and in particular whether this effect reﬂects some speciﬁc beneﬁts of
MBCT for those with a history of childhood abuse or neglect, or rather
the greater potential to beneﬁt from MBCT for those who are more vul-
nerable i.e. in this trial childhood trauma was closely associated with
overall risk of relapse over 12 months for the population as a whole.
The mean Jadad score was 2.7 based on all the included studies.
More speciﬁcally, for the three non-randomized trials the mean score
was 0, and for the 20 RCTs the mean score was 3.2. This suggests that
the included RCTs are generally of a high methodological quality (3.2
out of 4). The non-randomized studies had investigated rumination,
mindfulness and attention for negative information and a reduced inhi-
bition of attention. Mindfulness and rumination were investigated in
several relatively high quality trials that found a correlational or media-
tional effect. Attention for negative information and a reduced inhibi-
tion of attention were only studied in one non-randomized trial and
as such replication is warranted in a high quality RCT.
The study of speciﬁc mechanisms in MBCT treatment of recurrent
MDD is still in its early stages. Identifying mediators of change is the
ﬁrst step in establishing howMBCTmaywork in the treatment of recur-
rent MDD. Mediation analysis does not establish causality, but only
points to potential mechanisms (Kazdin, 2007). Although theoretically
plausible, we still do not know whether alterations in the proposed
mechanisms such as improved mindfulness skills are causal factors
leading to signiﬁcant reductions in depressive symptoms or relapse
risk. Changes in the studied mediators may be a marker for some
other effect that is causal (Segal et al., 2013). However, identiﬁcation
of mediators is the ﬁrst important step in establishing how MBCT
works (Kuyken et al., 2010), as it narrows down the search for ‘facilita-
tive ingredients for treatment to achieve change’ (Kazdin, 2007; p. 11).
Among all the proposed variables leading to therapeutic change, there is
a need for research that can uncover which variables aremost critical to
the change processes (Segal et al., 2013), and how the various variables
interact. Indeed, the investigated mechanisms of change may not be in-
dependent factors and there is a need for future research to investigate
the shared variance between the various variables. Further investigation
hereofmay enable candidate factors to be reduced to amore parsimoni-
ous number. In addition, to get a better indication of causal relations,
there is a need for more rigorous designs moving forward. It has been
suggested that a better measure of potential mechanisms could be
gained from employing extended temporal precedence measures, gra-
dient designs, componential control designs, and individual difference
designs (Kazdin, 2011; Kraemer et al., 2002; Kuyken et al., 2010;
Murphy et al., 2009). However, considering the possibility of reciprocal
causality between the various mechanisms and depressive symptoms,
some of these designs may also have limitations. Perhaps the under-
standing of the mechanisms in MBCT could be advanced by connecting
psychotherapy research with neuroscience and experimental science
research as suggested by Kazdin (2011) and Holmes et al. (2014). The
study of exposure-therapy related to fear conditioning, provides an ex-
ample of how experimental, neuroscientiﬁc and clinical approaches to
science on fear conditioning collectively can advance the understanding
of mechanisms in psychotherapy considerably (Ibid, 2011; 2014).
The number of studies investigating the neural correlates andmech-
anisms inMBCT treatment of recurrentMDDwas limited. The two stud-
ies included in this review that investigated neural correlates reported
inconsistent ﬁndings. A larger body of trials has investigated neural cor-
relates of mindfulness meditation, and may point towards interesting
avenues for future research. Of particular interest to MBCT treatment
of recurrent MDD may be structural changes to the hippocampus re-
ported in participants of the MBSR program (Hölzel, Carmody et al.,
2011),which have been hypothesized to be a centralmechanism in suc-
cessful treatment of depression (Eisch & Petrik, 2012). Furthermore, al-
tered amygdala reactivity has been suggested to play a role in
vulnerability to depressive relapse (Beck, 2008). Reduced amygdala
reactivity has been reported among mindfulness meditators, whereas
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the amygdala (Beck, 2008; Way, Creswell, Eisenberger, & Lieberman,
2010). Finally, Farb et al. (2010) found an indication of a shift from ‘me-
dial and left-lateralized cortical regions’ to more lateral viscerosomatic
representations (e.g. right insula) during a sad mood induction after
MBSR that was inversely related to depressive symptoms. Such studies
may beworth replicatingwithMBCT in a clinical sample with recurrent
major depressive disorder.
Trials investigating genetic and epigenetic mechanisms related to
MBCT treatment of recurrent MDD is in its infancy. However, Bakker
et al. (2014) found an indication that alterations in SNPs may underlie
a differential response to MBCT. In addition, recent studies suggest
that interventions with mindfulness meditation is linked with changes
in gene expression that may prevent inﬂammation and oxidative stress
implicated in the pathophysiology of MDD (Dahlgaard & Zachariae,
2014). Future research could beneﬁt from further unwrapping themod-
erating or mediating role of gene variation and gene expression related
toMBCT treatment of recurrentMDD. Notwithstanding the explanatory
gap between cognitive and physical levels of explanation, a pragmatic
clinical approach that employs biological sciences to investigate neural
and genetic predictive variables regarding relapse risk may be promis-
ing (Shulman, 2013). Furthermore, the investigation of genetic, neural,
and psychological mechanisms may open new promising avenues for
integrated research.
This review has evaluated clinical studies investigating mechanisms
of change speciﬁcally in MBCT for recurrent MDD. However, there may
be speciﬁc and non-speciﬁc mechanisms that have not yet been investi-
gated in MBCT treatment of recurrent MDD. Alternative mechanisms
have been identiﬁed in clinical trials investigating otherMBIs or popula-
tions, as well as suggested in broader theoretical models and reviews of
trans-diagnostic and trans-interventional mechanisms of change in
mindfulness-based interventions as a whole (e.g., Chiesa, Serretti, &
Jakobson, 2013; Farb et al., 2012; Garland et al., 2010; Grabovac et al.,
2011; Hölzel, Lazar et al., 2011; Jermann et al., 2013; Shapiro et al.,
2006; Vago & Silbersweig, 2012). Future research may beneﬁt from ex-
ploring a number of these potential mechanisms in MBCT for recurrent
MDD. For example, it has been suggested that MBIs may facilitate both
bottom-up and top-down emotion regulation (Chiesa et al., 2013;
Hölzel, Lazar et al., 2011). Mindful emotion regulationmay require pro-
cesses distinct from top-down emotion regulation strategies (e.g. cogni-
tive reappraisal), related to present moment sensation, acceptance and
suspension of judgment (Farb et al., 2012; Sipe & Eisendrath, 2012).
More speciﬁcally, it has been suggested that mindfulness meditation
may facilitate exposure, retrieval and reconsolidation during unpleasant
emotional and bodily experiences, leading to an overwriting of previ-
ously learned stimulus–response associations (Hölzel, Carmody et al.,
2011). In support of bottom-up processes, neuroimaging trials have in-
dicated reduced prefrontal emotion regulation, and increased functional
and structural changes in interoceptive and sensory regions such as the
insula, somatosensory cortex and parietal regions associated with de-
creased reactivity to negative emotions and reduced depressive symp-
toms following training in mindfulness meditation (Farb et al., 2012;
Hölzel, Lazar et al., 2011). The insula in particular has been associated
with body awareness, modulation of subjective unpleasantness and va-
lence of body states, and may play a central role in regulating
depressogenic affect and related embodied sensations (Craig, 2002;
Damasio & Calhalvo, 2013; Farb et al., 2012). Neuroimaging has also in-
dicated thatMBIsmay lead to cortical and subcortical plasticity, facilitat-
ing an increased ability to cognitively reappraise emotional reactions
(Hölzel, Lazar et al., 2011). Hence, it may be that MBIs may facilitate
both bottom-up and top-down emotion regulation strategies that to-
gether reduce vulnerability for relapse/recurrence.
MBCT may also facilitate changes in how the participant relates to
self and others, andMBIs have been hypothesized to lead tomore adap-
tive interpersonal communication, and modiﬁcation of dysfunctional
cognitive biases and beliefs regarding the self, other and the world(Kabat-Zinn, 2013; Siegel, 2001; Vago & Silbersweig, 2012). Addressing
interpersonal relations and dysfunctional cognitive biases and beliefs
are central to other psychotherapeutic depression treatments such as
cognitive behavioral therapy (CBT) and interpersonal therapy (IPT). Fu-
ture research needs to determine to what extent MBCTmay affect these
variables, and their relation to relapse/recurrence vulnerability in a clin-
ical sample with recurrent major depressive disorder.
Many of the practices and proposedmechanisms inMBCT have line-
age in Buddhist psychology.While based in different epistemologies and
languages, increasingly the ﬁeld has started to explore the synergies be-
tween Buddhist models and cognitive science (Grabovac et al., 2011;
Teasdale & Chaskalson, 2011). Within Buddhist models (e.g., the
abhidhamma) stimuli (from each of the ﬁve senses and the ‘mind’) are
quickly identiﬁed as pleasant, unpleasant or neutral. The mind can re-
spond to these associations through attachment or aversion, both of
which can trigger patterns of reactivity that create suffering. Prolifera-
tive thinking can easily escalate into negative associative thinking and
affective states akin to depression. When this is repeated enough
times, views and behaviors become more habitual. The parallels with
cognitive accounts are striking and future researchmay beneﬁt from in-
vestigating such synergies further.
It is currently unknown whether the studied mediators and pro-
posed mechanisms such as mindfulness, rumination, compassion and
decentering are unique to MBCT as a treatment of recurrent MDD.
Other therapies such as CBT, IPT, and antidepressant medicine (ADM)
may also impact these variables. Both ADM and CBT have been associat-
ed with increased metacognitive awareness and reduced rumination
(Bieling et al., 2012; Teasdale et al., 2002). As trait mindfulness has
been inversely correlated with depressive symptoms (e.g. Sanders &
Lam, 2010; Way et al., 2010), CBT, IPT and ADM treatment of recurrent
MDDmay also affect measures of mindfulness. It would be relevant for
future research to explore the degree to which other established thera-
pies of recurrentMDD impact mindfulness skills, and whether a greater
change in mindfulness skills is associated with MBCT. However, it re-
mains a challenge to determine which effects are byproducts and
which effects are causal. Two studies reported ﬁndings indicating treat-
ment speciﬁcity. Kuyken et al. (2010) found that MBCT patients had
higher cognitive reactivity post-treatment in comparison with m-ADM
controls, and that cognitive reactivity predicted poorer outcome only
for m-ADMpatients, but not forMBCT patients. In addition, a signiﬁcant
interaction between self-compassion and cognitive reactivitywas found
only in the MBCT group, indicating that self-compassion could have re-
duced the link between cognitive reactivity and relapse risk in theMBCT
group. Bieling et al. (2012) found signiﬁcant increases in wider experi-
ences and decentering post-MBCT, which was not present in the m-
ADM control group. Both studies compared MBCT treatment with m-
ADM, and the ﬁndings showed an indication of equal efﬁcacy, hence
suggesting that different mechanisms of change may be employed in
the respective therapies. It would be relevant for future research to ex-
plore howMBCT compareswith other evidence-based psychotherapeu-
tic treatments of depression (e.g. CBT or IPT) on both non-speciﬁc and
speciﬁc mechanisms. Despite the different theoretical models, there
may be an overlap in mechanisms of change and speaking of potential
trans-interventionalmechanisms (e.g. emotional exposure in a compas-
sionate therapeutic environment). It may also be that the respective
therapies primarily work through different focus points (e.g., cognitive
biases and beliefs; interpersonal relationships; and compassion and
decentering), but all affect an interconnected constellation of cognitive,
emotional, bodily and behavioral symptoms.
Most of the reviewed studies have investigated mediators in MBCT
treatment for patients with recurrent MDD in remission. Yet, a growing
body of evidence suggests that MBCT can also be efﬁcient for MDD pa-
tients who are currently symptomatic (e.g. Manicavasgar, Parker, &
Perich, 2012; Van Aalderen et al., 2012). Van Aalderen et al. (2012) in-
cluded currently symptomatic patients and found that the reduction
of depressive symptoms was mediated by reduced rumination and
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depressed.However,MBCT treatment of a current episode of depression
may entail additional challenges as patients may have highly prevalent
depressogenic biases and be behaviorally restricted (Beck & Alford,
2009). Future research may beneﬁt from exploring whether different
mechanisms are involved in MBCT treatment of currently symptomatic
recurrent MDD. For example, MBCT may modify depressogenic cogni-
tive biases — a target of traditional CBT for acute depression.
The majority of the reviewed studies investigated treatment of re-
current depression as one coherent population. However, it has been
suggested that MBCT might be particularly effective for particular sub-
group populations, e.g. patients with earlier ﬁrst episode onset and
childhood adversity, and less effective for populations where episodes
are provoked by stressful life events (Ma & Teasdale, 2004). Considering
thatWilliams et al. (2014) found thatMBCT provided signiﬁcant protec-
tion against relapse for participants with increased vulnerability due to
a history of childhood trauma, but showed no signiﬁcant advantage in
comparison to either CPE and TAU over the whole group of patients, fu-
ture research may beneﬁt from studying potential mechanisms such as
mindfulness skills in different base populations among MDD patients.
Generally, there is a need to investigate developmental, etiological and
gender variations in mechanisms and treatment effect for MBCT treat-
ment of recurrent MDD. Considering the heterogeneity of recurrent
MDD an improved understanding of moderating patient characteristics
could enable improved targeting.
Mechanisms of change may be directionally affected by moderating
variables. Therapist competence and adherence may facilitate an in-
crease in potential mechanisms of change such as mindfulness skills.
The moderating role of practice motivation and sustained practice dur-
ing and after treatment would also be relevant to explore. A recent
study found that participants who engaged in formal home practice at
least 3 days aweek during the treatment phasewere almost half as like-
ly to relapse as thosewho reported fewer days of formal practice (Crane
et al., 2014). Future studies may beneﬁt from exploring the moderating
impact on both outcome and mechanisms measures.
Ensuring proper treatment ﬁdelity may directly be related to the
ability to ﬁnd a treatment ormediation effect. The importance of trainer
competence, adherence and training, have repeatedly been highlighted
in the literature (Crane et al., 2012). Furthermore, the depth of the
trainer's personal mindfulness practice as well as the trainer's ability
to embody compassion and mindfulness have been highlighted as
central to positive outcomes (Kabat-Zinn et al., 2011). Future studies
should aim to report in detail on how treatment ﬁdelity is measured
and ensured, and seek to follow established guidelines such as
Mindfulness-Based Interventions—Teaching Assessment Criteria Scale,
which assesses therapist adherence to the MBCT protocol and compe-
tence in its delivery (Williams et al., 2014; Crane et al., 2013; Crane
et al., 2012.).
Several studies employed post-treatment depressive symptoms as a
marker for relapse risk. Although post-treatment depressive symptoms
are generally considered a robust marker for relapse risk (Paykel, 2008)
and a non-continuousmeasure of relapse inmediational analysis can be
problematic, future studies should ideally employ measures of both
post-treatment depressive symptoms and relapse. Furthermore, it is
unclear whether post hoc or a priori hypotheses were employed in
the majority of the reviewed studies. As negative ﬁndings may not al-
ways be published, it is currently not possible to estimate the potential
prevalence of a ‘ﬁle-drawer phenomena’ or publication bias in the ﬁeld.
Consequently,wewould recommend that researchers in theﬁeld aim to
publish study protocols specifying a priori hypotheses, and in general
aim to employ pre-speciﬁed hypotheses, whenever possible.
This review has several strengths. Most importantly, it is to our
knowledge the ﬁrst systematic review speciﬁcally on potential mecha-
nisms of change in MBCT treatment of recurrent MDD. As such the re-
view supplements existing reviews of trans-diagnostic mechanisms of
change in mindfulness-based interventions as a whole (e.g. Chiesaet al., 2013; Hölzel, Carmody et al, 2011; Vago & Silbersweig, 2012),
by providing important information on potentialmechanisms of change
speciﬁcally in MBCT treatment of recurrent MDD, as well as a direction
for future research. Furthermore, study aims, inclusion and evaluation
criteria were generally pre-speciﬁed and highly focused. To limit selec-
tion bias, the review was conducted in adherence to the Preferred
Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)
(Moher et al., 2009). The review included an evaluation i.e. modiﬁed
Jadad criteria (Coelho et al., 2007; Jadad et al., 1996) of themethodolog-
ical quality of the included studies, providing a measure of the extent
the examined studies reduced risk of selection and expectancy bias. Fi-
nally, we included an evaluation of the causal speciﬁcity of studies in-
vestigating proposed mechanisms, providing a measure of the level of
mechanism speciﬁcity.
Due to the broad range of potential mechanisms investigated,
limited statistical power and study heterogeneity, it was not appropri-
ate to conduct a meta-analytical evaluation. However, as the number
of mediational studies expands this could be a next appropriate step
by focusing on speciﬁc proposed mechanisms such as mindfulness,
self-compassion, rumination or worry. This review on the other hand
provides an overview by including a broad range of studies investigat-
ing different potential change mechanisms in MBCT. The review is in-
herently limited by the results of the systematic search strategy i.e.
the clinical studies that have investigatedmechanisms of change specif-
ically inMBCT for recurrentMDD. These have predominantly focused on
relapse/recurrence or residual depressive symptoms as outcome mea-
sures, andwe know little about themechanisms bywhichMBCT affects
other outcome variables such as social and work adjustment, life satis-
faction, and attendant reductions in health care utilization and costs,
nor speciﬁc symptoms such as residual somatic symptoms.
Moving the ﬁeld of research from mediation research to an investi-
gation of mechanisms is a challenge facing researchers of evidence-
based psychotherapies in general (Kazdin, 2009). The scientiﬁc study
of therapeutic mechanisms of change is complex, perplexing and ‘cer-
tainly not an easy path on which to embark’ (Kazdin, 2011, p. 426).
MBCT may work for multiple reasons, and two recurrently depressed
patients receiving MBCT may respond for different reasons. Speciﬁc
and non-speciﬁc factors as well as linear and non-linear processes
may interact and synergistically bring about the preventative treatment
effect. However, these complexities are important to investigate fur-
ther: ‘because the best patient care will come from ensuring that the opti-
mal variation of treatment is provided. Understanding mechanisms of
treatment is the path toward improved treatment.’ (Kazdin, 2011, p. 426).
In conclusion, in linewith theoretical predictions there is an increas-
ing body of clinical trials suggesting that alterations in mindfulness,
worry, meta-awareness, and self-compassion are associated with, pre-
dict ormediate reduction in post-treatment depressive symptomsor re-
lapse risk, and thus could be key contributory factors to the beneﬁcial
effects of MBCT in the treatment of recurrent MDD. The role of rumina-
tion is less clear, and needs to be explored further in future trials. In ad-
dition to the theoretical predicted variables, a number of additional
psychological, neural and genetic factors have been suggested to be po-
tential mechanisms in MBCT treatment of recurrent MDD, and are wor-
thy of further investigation. Currently, there is a lack of replicated
studies that can convey the speciﬁc and non-speciﬁc mechanisms re-
sponsible for change. Future studies need to employ more rigorous de-
signs that can assess a greater level of causal speciﬁcity of the potential
mechanisms of change.
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